Global Information
회사소개 | 문의

전립선암 : 파이프라인 리뷰

Prostate Cancer - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 06월 상품 코드 232770
페이지 정보 영문 2069 Pages
가격
US $ 2,500 ₩ 2,851,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,702,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,553,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전립선암 : 파이프라인 리뷰 Prostate Cancer - Pipeline Review, H1 2018
발행일 : 2018년 06월 페이지 정보 : 영문 2069 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

전립선암은 전립선에서 발생하는 암의 일종으로, 남성, 특히 고령의 남성에게 발병합니다. 주요 증상으로는 배뇨장애와 소변줄기 약화, 혈뇨, 허리, 엉덩이, 허벅지 등의 통증 등이 있습니다. 질병소인으로는 연령, 가족력, 비만 등이 있습니다. 주요 치료법은 외과 수술, 화학요법, 방사선 치료 등이 있습니다.

세계 각국에서의 전립선암(Prostate Cancer) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

전립선암 개요

치료제 개발

전립선암 : 기업에서 개발중인 치료제

전립선암 : 대학/기관에서 연구중인 치료제

전립선암 : 파이프라인 제품 개요

전립선암 : 기업에서 개발중인 제품

전립선암 : 대학/기관에서 연구중인 제품

전립선암 치료제 개발에 참여하고 있는 기업

전립선암 : 치료제 평가

약제 개요

전립선암 : 휴지중인 프로젝트

전립선암 : 개발이 중지된 제품

전립선암 : 제품 개발 마일스톤

부록

KSM 16.08.03

List of Tables

  • Number of Products under Development for Prostate Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Prostate Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
  • Prostate Cancer - Pipeline by 4SC AG, H1 2018
  • Prostate Cancer - Pipeline by AB Science SA, H1 2018
  • Prostate Cancer - Pipeline by AbbVie Inc, H1 2018
  • Prostate Cancer - Pipeline by Abpro, H1 2018
  • Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
  • Prostate Cancer - Pipeline by ADC Therapeutics SA, H1 2018
  • Prostate Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2018
  • Prostate Cancer - Pipeline by Advantagene Inc, H1 2018
  • Prostate Cancer - Pipeline by Advaxis Inc, H1 2018
  • Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
  • Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
  • Prostate Cancer - Pipeline by Akshaya Bio Inc, H1 2018
  • Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018
  • Prostate Cancer - Pipeline by Alissa Pharma, H1 2018
  • Prostate Cancer - Pipeline by ALRISE Biosystems GmbH, H1 2018
  • Prostate Cancer - Pipeline by Altor BioScience Corp, H1 2018
  • Prostate Cancer - Pipeline by Ambrx Inc, H1 2018
  • Prostate Cancer - Pipeline by Amgen Inc, H1 2018
  • Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H1 2018
  • Prostate Cancer - Pipeline by AndroScience Corp, H1 2018
  • Prostate Cancer - Pipeline by AnGes Inc, H1 2018
  • Prostate Cancer - Pipeline by AntiCancer Inc, H1 2018
  • Prostate Cancer - Pipeline by Antigen Express Inc, H1 2018
  • Prostate Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018
  • Prostate Cancer - Pipeline by Apcure SAS, H1 2018
  • Prostate Cancer - Pipeline by Aphios Corp, H1 2018
  • Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2018
  • Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H1 2018
  • Prostate Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
  • Prostate Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
  • Prostate Cancer - Pipeline by Armour Therapeutics Inc, H1 2018
  • Prostate Cancer - Pipeline by ArQule Inc, H1 2018
  • Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
  • Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018
  • Prostate Cancer - Pipeline by Arvinas Inc, H1 2018
  • Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018
  • Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2018
  • Prostate Cancer - Pipeline by Athenex Inc, H1 2018
  • Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Prostate Cancer - Pipeline by Autolus Ltd, H1 2018
  • Prostate Cancer - Pipeline by Avivia BV, H1 2018
  • Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
  • Prostate Cancer - Pipeline by Bayer AG, H1 2018
  • Prostate Cancer - Pipeline by BeiGene Ltd, H1 2018
  • Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2018
  • Prostate Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
  • Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
  • Prostate Cancer - Pipeline by BioAtla LLC, H1 2018
  • Prostate Cancer - Pipeline by BioNTech AG, H1 2018
  • Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
  • Prostate Cancer - Pipeline by Blirt SA, H1 2018
  • Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Prostate Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Prostate Cancer - Pipeline by Bukwang Pharm Co Ltd, H1 2018
  • Prostate Cancer - Pipeline by Camurus AB, H1 2018
  • Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2018
  • Prostate Cancer - Pipeline by CanBas Co Ltd, H1 2018

List of Figures

  • Number of Products under Development for Prostate Cancer, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Top 10 Routes of Administration, H1 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 118, 103, 7, 243, 34 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 20, 58 and 21 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Prostate Cancer - Overview
  • Prostate Cancer - Therapeutics Development
  • Prostate Cancer - Therapeutics Assessment
  • Prostate Cancer - Companies Involved in Therapeutics Development
  • Prostate Cancer - Drug Profiles
  • Prostate Cancer - Discontinued Products
  • Prostate Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research